Shares in Issue
The current number of ordinary shares in issue as at 9th June 2022 is 290,033,335. 11% of Psych Capital ordinary shares are held in public hands. 

Options / Warrants
At Admission share options will have been granted under a share option scheme over 31,835,832 Ordinary Shares to the Directors, Proposed Director, Technical Advisory Board, Founders and employees of the Company, representing 10.98 per cent. of the Issued Share Capital immediately following Admission. The Options will be granted with effect from Admission and will be capable of being exercised, for a period of 2 years from the date of Admission, and vest immediately.

Restrictions on Share Transfer
Ordinary Shares are freely transferrable

Significant Shareholders
Percentage of issued share capital on Admission
Prohibition Holdings Limited – (31.03%)
Christopher Potts – (18.89%)
Oscillate plc – (16.15%)
Peterhouse Capital Limited – (5.53%)
Stephen Murphy – (4.22%)
William Potts (3.70%)
Robert Reid – (3.63%)

The Directors are committed to maintaining high standards of corporate governance, and, so far as is practicable given the Company’s size and nature, to comply with the QCA Code.

The Board holds at least six board meetings a year and will also hold timely board meetings as and when issues arise which require its attention. The Board is responsible for the management of the business of the Company, setting the strategic direction of the Company.

The Board has 4 formally established committees – Remuneration, Audit, AQSE Rules Compliance and an Executive Committee. The Board has also established a Psychedelic Medicines Technical Advisory Board consisting of industry experts.

The Company has established Financial Position and Prospects procedures and adopted an anti-bribery and corruption policy.

Investor Information

17 Hanover Square,
London W1S 1BN
United Kingdom

Tel: +442038387621
Email: i[email protected]